About Future Standard

• Founded: 2018

• Headquarters: London, United Kingdom

• AUM: Approximately $5bn (as of 2024)

• Strategy: Lower mid-market buyout, B2B services and technology

• Thesis: Targets founder-owned businesses in fragmented sectors with digitization opportunities and recurring revenue models

• Track record: Previous fund closed at $1.2bn in 2021; portfolio includes software, healthcare services, and business process outsourcing platforms

• Leadership: Founded by former mid-market PE investors with prior exits totaling over $8bn in aggregate value

Future Standard closed its latest flagship fund at approximately $3bn, marking a 2.5x increase over its prior vintage. The fund will continue the firm's focus on acquiring lower mid-market B2B businesses, targeting enterprise values between $100m and $500m. The raise took 14 months and drew commitments from North American and European institutional LPs, including pension funds and insurance companies. The fund's first-close occurred in Q2 2023 at $2.1bn, with oversubscription leading to a hard cap deployment.

The $3bn close positions Future Standard in the crowded lower mid-market segment where capital has concentrated as larger buyout firms move downmarket and specialist managers scale up. Recent comparable raises include Abry Partners' $5.1bn close in late 2023 and Novacap's $2.8bn fund in early 2024, both targeting similar deal sizes. Pricing discipline will matter — secondary market data shows 2021–2022 vintage funds in this segment trading at 5–10% discounts asMarkToMarket adjustments bite and exit timelines extend.

What to watch is whether Future Standard deploys faster than its peer set. Funds of this size in the lower mid-market now face 4–5 year investment periods, up from 3 years pre-2020, as competitive auction processes slow deal velocity. If the firm maintains its historical 12–15 platform acquisitions per fund, average hold periods could stretch to 6–7 years, compressing net IRRs even if exit multiples recover. The fund's LP base skews toward those seeking current income, which may pressure the GP to prioritize dividend recaps over patient compounding — a tension worth monitoring as the portfolio matures.

Source: Secondaries Investor